Table 1.

Patient characteristics. Abbreviation: IMiD, immunomodulatory drug.

Characteristic (N=12)	Median (range) or N (%)
Female/Male	6 (50%) / 6 (50%)
Age at enrollment (years)	68 (48 – 85)
Number of prior lines of therapy	5 (4–15)
ISS staging at diagnosis
Stage I	3 (25%)
Stage II	3 (25%)
Stage III	3 (25%)
Unknown/missing	3 (25%)
Prior autologous transplant
Yes	10 (83%)
No	2 (17%)
Prior radiation
Yes	4 (33%)
No	8 (67%)
Serum electrophoresis and immunofixation
Positive	11 (92%)
IgG κ	5 (45%)
IgG λ	3 (27%)
IgG κ	2 (18%)
Serum unknown, κ	1 (9.1%)
Negative**	1 (8.3%)
Cytogenetic risk*
Low	4 (33%)
Standard	3 (25%)
High	5 (42%)
Del 17p	2 (40%)
Gain 1q	2 (40%)
t(4;14)	1 (20%)
PI refractory
Yes	10 (83%)
No	2 (17%)
IMiD refractory
Yes	10 (83%)
No	2 (17%)
Double refractory (bortezomib/lenalidomide)
Yes	8 (67%)
No	4 (33%)

^*High-risk cytogenetics was defined as Del 17p, Gain 1q, t(4;14), or t(4;16).

^**One patient had measurable free light chains.